Octamers and nanoparticles as hemoglobin based blood substitutes

Area of Science:

• Biotechnology
• Hematology
• Biomedical Engineering

Background:

• Advancements in biotechnology and circulatory system understanding aid blood substitute development.
• Hemoglobin (Hb)-based solutions face challenges in optimizing oxygen affinity, oxidation rate, cooperativity, and material sourcing.
• Genetic engineering has identified new globins but not in sufficient quantities for transfusion needs.

Purpose of the Study:

• To review fundamental parameters for hemoglobin-based blood substitutes.
• To discuss the trade-offs between coupled parameters like oxygen affinity and oxidation rate.
• To explore strategies for optimizing oxygen transporter size, specifically Hb octamers and nanoparticle-integrated Hb.

Main Methods:

• Literature review of current biotechnologies and understanding of the circulatory system.
• Analysis of genetic engineering outcomes for novel globin discovery.
• Focus on two size-based strategies for oxygen transporters: Hb octamers and nanoparticle integration.

Main Results:

• Coupled parameters, such as oxygen affinity and oxidation rate, necessitate compromises in achieving optimal blood substitute characteristics.
• Novel globins discovered via genetic engineering are not yet available in quantities sufficient for widespread transfusion use.
• Hb octamers and nanoparticle-integrated Hb represent two distinct approaches to managing oxygen transporter size.

Conclusions:

• Developing ideal hemoglobin-based blood substitutes requires careful consideration and compromise of fundamental properties.
• Further research into genetic engineering and nanoparticle integration is crucial for meeting the demand for blood transfusions.
• Optimizing oxygen transporter size is a key strategy in advancing blood substitute technology.